Myths and facts in the use of anti-inflammatory drugs
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Because of the prominence of pain-related conditions and the growing complexities of clinical management we aimed to explore and attempt to dispel the several myths that surround these serious therapeutic issues. AIMS: We aimed to provide a careful analysis of the evidence and draw factually based guidance for physicians who manage the broad range of patients with pain. METHODS: Current myths were identified based on the authors' clinical, scientific, and academic experience. Each contributor addressed specific topics and made his own selection of primary references and systematic reviews by searching in MEDLINE, EMBASE, and CINAHL databases (1990-2008) as well as in the proceedings of the major digestive and rheumatology meetings. The writing and references provided by each contributor were collectively analyzed and discussed by all authors during several meetings until the final manuscript was prepared and approved. RESULTS: Seven major 'historical' myths that may perpetuate habits and beliefs in clinical practice were identified. Each of them was thoroughly examined and dispelled, drawing conclusions that should help guide physicians to better manage patients with pain. CONCLUSIONS: Pain relief must be considered a human right, and patients with osteoarthritis pain should be treated appropriately with analgesic or/and anti-inflammatory drugs. The risk of gastrointestinal (GI) complications with traditional non-steroidal anti-inflammatory drugs (t-NSAIDs) is present from the first dose (with both short-term and long-term use), and strategies to prevent GI complications should be considered regardless of the duration of therapy. Compared with t-NSAIDs, coxib use is associated with a small but significant reduction of dyspepsia. While protecting the stomach, proton pump inhibitors do not prevent NSAID-induced intestinal damage. To this end, coxib therapy could be the preferred option, although further randomized studies are needed. A substantial number of patients who need NSAIDs are also taking low-dose aspirin for cardiovascular prophylaxis. From a GI perspective, the combination of aspirin plus a coxib provides a preferred option compared with aspirin plus a t-NSAID, for patients at high GI risk. As the incidence of renovascular adverse effects with t-NSAIDs and coxibs is similar, blood pressure should be monitored and managed appropriately in patients taking these drugs, although they should be avoided in those with severe congestive heart failure. Due to increased cardiovascular risk, which is dependent on the dose, duration of therapy, and base-line cardiovascular risk, both t-NSAIDs and coxibs should be used with caution in patients with underlying prothrombotic states and/or concomitant cardiovascular risk factors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050493 · Cited by 2,519 · cited 1×
“Cyclo-oxygenase 2 (COX-2)-selective inhibitors (often referred to as coxibs (15)) were introduced as a safer alternative to traditional NSAIDs (tNSAIDs) based on an improved GI safety profile but were subsequently found to be associated with an increase in cardiovascular (CV) adverse events (16,17).”
BackgroundRisk of Cardiovascular Events Associated with Selective COX-2 Inhibitors
Mukherjee, D. (2001) · JAMA · doi:10.1001/jama.286.8.954 · Cited by 1,741
Zhang, W., Doherty, M., Leeb, B. F., Alekseeva, L., Arden, N. K., Bijlsma, J. W., Dinçer, F., Dziedzic, K., Häuselmann, H. J., Herrero-Beaumont, G., et al. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.062091 · Cited by 1,338
Dalton, S. O., Johansen, C., Mellemkjær, L., Sørensen, H. T., Nørgård, B., & Olsen, J. H. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.1.59 · Cited by 389
Meta-analysis of Cyclooxygenase-2 Inhibitors and Their Effects on Blood Pressure
(2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.5.ioi50013 · Cited by 329
WESSINGER, S., KAPLAN, M., CHOI, L., WILLIAMS, M., LAU, C., SHARP, L., CROWELL, M. D., KESHAVARZIAN, A., & JONES, M. P. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.02859.x · Cited by 96 · cited 1×
“Gastrointestinal bleeding may be generalized (109) or localized to the upper gastrointestinal tract (110 112).”
Background
Cited by
Harirforoosh, S., Asghar, W., & Jamali, F. (2014) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3vw2f · Cited by 960
for the SIF-AIGO-FIMMG Group, Scarpignato, C., on behalf of the Italian Society of Pharmacology, T. I. A. O. H. G., Gatta, L., Zullo, A., & Blandizzi, C. (2016) · BMC Medicine · doi:10.1186/s12916-016-0718-z · Cited by 469
“5 %, available evidence (from both RCTs and observational studies) shows that the risk of GI complications is constant over time, either during shortterm or long-term NSAID use [170].”
BackgroundInfluentialSelf-citationProton Pump Inhibitors Exacerbate NSAID-Induced Small Intestinal Injury by Inducing Dysbiosis
Wallace, J. L., Syer, S., Denou, E., de Palma, G., Vong, L., McKnight, W., Jury, J., Bolla, M., Bercik, P., Collins, S. M., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.06.075 · Cited by 460
Pathi, S., Jutooru, I., Chadalapaka, G., Nair, V., Lee, S.-O., & Safe, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048208 · Cited by 127
“concern regarding the adverse gastrointestinal side-effects of aspirin [2,3,34] and in the future, these may be circumvented by using NO-NSAIDs.”
BackgroundYan, L., Li, D., Li, S., Jiao Li, J., Du, G., Liu, H., Zhang, J., Li, X., Fan, Z., Jiu, J., et al. (2024) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.154432 · Cited by 20
Metadata
- Authors
- Hunt, R. H., Lanas, A., Stichtenoth, D. O., & Scarpignato, C.
- Venue
- Annals of Medicine
- Publisher
- Informa UK Limited
- Published
- 2009-01
- Volume
- 41
- Issue
- 6
- Pages
- 423-437
- ISSN
- 0785-3890 (ISSN-L)
- 1365-2060
- OpenAlex
- W2165006671
- Cited by
- 55
- References
- 6
- FWCI
- 2.99
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Myths and facts in the use of anti-inflammatory drugs. https://app.cochat.ai/papers/10.1080/07853890902887295
- The paper
- Hunt, R. H., Lanas, A., Stichtenoth, D. O., & Scarpignato, C. (2009). Myths and facts in the use of anti-inflammatory drugs. Annals of Medicine. https://doi.org/10.1080/07853890902887295
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.